# A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy

> **NCT04418297** · PHASE1 · TERMINATED · sponsor: **Celltrion** · enrollment: 23 (actual)

## Conditions studied

- Cardiomyopathy, Hypertrophic Obstructive

## Interventions

- **DRUG:** CT-G20
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04418297
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-23
- **Primary completion:** 2022-11-22
- **Final completion:** 2022-11-22
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** The termination criteria of the protocol was met during dose escalation
- **Last updated:** 2023-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04418297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04418297, "A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04418297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*